FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems known as sprue-like enteropathy.
Symptoms of sprue-like enteropathy include severe, chronic diarrhea with substantial weight loss.
FDA has approved changes to the labels of these drugs to include this concern. Sprue-like enteropathy has not been detected with sartans other than Olmesartan.
Olmesartan medoxomil is an angiotensin II receptor blocker ( sartan; ARB ) approved for the treatment of high blood pressure, alone or with other antihypertensive agents, and is one of eight marketed ARB drugs.
Health care professionals should tell patients to contact them if they develop severe, chronic diarrhea with substantial weight loss while taking an Olmesartan-containing product, even if it takes months to years for symptoms to develop.
Patients should contact their health care professional right away if they take an Olmesartan-containing product and experience severe diarrhea, diarrhea that does not go away, or significant weight loss. ( Xagena )
Source: FDA, 2013